What is Xilio Therapeutics, Inc.'s market cap?

Xilio Therapeutics, Inc. (XLO) has a market capitalization of $60.5M and trades on NASDAQ.

Who are Xilio Therapeutics, Inc.'s competitors?

Xilio Therapeutics, Inc.'s key competitors include CytomX Therapeutics, Amgen, Janux Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Xilio Therapeutics, Inc. partner with?

Xilio Therapeutics, Inc.'s notable partners include AbbVie, Gilead Sciences, Inc..

What subsidiaries does Xilio Therapeutics, Inc. have?

Xilio Therapeutics, Inc.'s subsidiaries include Xilio Development, Inc..

Where is Xilio Therapeutics, Inc. headquartered?

Xilio Therapeutics, Inc. is headquartered in United States of America and employs approximately 73 people. It has been publicly traded since 2021.

Xilio Therapeutics, Inc.

XLO

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing a new class of tumor-activated immuno-oncology (I-O) therapies.

Market cap

$60.49M+57.0%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$12.7MBeat by $4.1M EPS-$0.58Beat by $0.08

Read the full report

Next report

Aug 13, 2026 (in a month)

Revenue estimate$12.7M

EPS estimate-$0.59

Competitors

By market cap

Amgen$196.25B+24.6%

Immunome$2.7B+262%

Janux Therapeutics$1.0B-28.0%

CytomX Therapeutics$861.0M+131%

Elicio Therapeutics, Inc.$91.7M-32.6%

Xilio Therapeutics, Inc.$60.5M+67.1%

Instil Bio$51.9M-66.5%

Werewolf Therapeutics, Inc.$18.4M-61.0%

By revenue growth

Janux Therapeutics+47.1%

Amgen+9.1%

Immunome-63.3%

CytomX Therapeutics-75.9%

By net margin

Amgen20.96%+3.6pp

CytomX Therapeutics-166.4%-195pp

Janux Therapeutics-833.6%-0.9pp

Immunome-5,593.85%-3,719pp

Profile

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing a new class of tumor-activated immuno-oncology (I-O) therapies. The company utilizes a proprietary masking technology to design biologics that remain inactive in healthy tissue and selectively activate within the tumor microenvironment to maximize anti-tumor potency while minimizing systemic toxicity.

Competitive position

A clinical-stage innovator in the masked biologic space with validated technology and strategic partnerships with major pharmaceutical players.

GeographiesUnited States

Customer segmentsBiopharmaceutical companies

Business modelR&D, Licensing, B2B

SuppliersSpecialized contract manufacturing organizations, Laboratory equipment suppliers, Protease research providers

CustomersGlobal pharmaceutical companies, Oncology patients, Clinical trial sites

CountryUnited States of America

Listed2021

Employees73.0

CEORene Russo

SectorHealthcare

IndustryBiotechnology

Websitexiliotx.com

FilingsSEC EDGAR

Questions, answered.

What is Xilio Therapeutics, Inc.'s market cap?: Xilio Therapeutics, Inc. (XLO) has a market capitalization of $60.5M and trades on NASDAQ.
Who are Xilio Therapeutics, Inc.'s competitors?: Xilio Therapeutics, Inc.'s key competitors include CytomX Therapeutics, Amgen, Janux Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Xilio Therapeutics, Inc. partner with?: Xilio Therapeutics, Inc.'s notable partners include AbbVie, Gilead Sciences, Inc..
What subsidiaries does Xilio Therapeutics, Inc. have?: Xilio Therapeutics, Inc.'s subsidiaries include Xilio Development, Inc..
Where is Xilio Therapeutics, Inc. headquartered?: Xilio Therapeutics, Inc. is headquartered in United States of America and employs approximately 73 people. It has been publicly traded since 2021.